3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia
9
Leukemia, Myeloid, Acute
7
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Primary Immunodeficiency Diseases
3
Multiple Myeloma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Recurrence
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Interventions
Rituximab
4
Doxorubicin
3
Cyclophosphamide
3
Vincristine
2
Prednisone
2
Etoposide
2
pomalidomide
1
merphos
1
fludarabine
1
brincidofovir
1
Zidovudine
1
Tomography, X-Ray Computed
1
Polymerase Chain Reaction
1
Nivolumab
1
Methotrexate
1
Leucovorin
1
Interferons
1
In Situ Hybridization
1
Immunohistochemistry
1
Hydroxyurea
1
Flow Cytometry
1
Echocardiography
1
EPOCH protocol
1
Cytogenetic Analysis
1
Caves
1
Brentuximab Vedotin
1
Blotting, Western
1
AP 1903 reagent
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
AP 1903 reagent
×
Lymphoid
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled